Filho, Otto Metzger http://orcid.org/0000-0003-0792-0320
Giobbie-Hurder, Anita
Lin, Nancy U.
Faggen, Meredith
Come, Steven
Openshaw, Thomas
Constantine, Michael
Walsh, Jeanna
Freedman, Rachel A.
Schneider, Bryan
Burstein, Harold J.
Mayer, Erica L.
Clinical trials referenced in this document:
Documents that mention this clinical trial
A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer
https://doi.org/10.1007/s10549-020-05928-4
Funding for this research was provided by:
Eisai, Inc
Article History
Received: 26 June 2020
Accepted: 4 September 2020
First Online: 6 October 2020
Compliance with ethical standards
:
: O. Metzger Filho reports research funding to institution from Abbvie, Cascadian Therapeutics, Eisai, Pfizer, Roche/Genentech, and Susan G. Komen for the Cure; consulting/advisory roles for Abbvie, G1 Therapeutics, and Groupo Oncoclinicas (Brazil); and honoraria from Roche (Brazil); travel/accommodations/expenses from Grupo Oncoclinicas. N.U. Lin reports research funding to institution from Seattle Genetics, Genentech, Pfizer, Merck; advisory board roles for Daichii Sankyo, Puma, Seattle Genetics; and royalties from UpToDate. R. Freedman reports research funding to institution from Eisai and Puma. E.L. Mayer reports research funding to institution from Pfizer, Eisai. Advisory Board: Lilly, Novartis, and Eisai. All other authors report no disclosures.
: This trial was approved by the individual institutional review boards at participating cancer centers and conducted according to the provisions of the Declaration of Helsinki and Good Clinical Practice.
: Informed consent was obtained from all individual participants included in the study. All patients provided written informed consent before any study-related procedures.
: This trial was approved by the individual institutional review boards at participating cancer centers and conducted according to the provisions of the Declaration of Helsinki and Good Clinical Practice.